Literature DB >> 19673680

Limit of viability in Japan: ethical consideration.

Hiroshi Nishida1, Izumi Sakuma.   

Abstract

Viability means "the quality or state of being able to live, grow and develop." Limit of viability has been changed along with the advancement of perinatal and neonatal medicine. The viability limit defined in the Japanese Motherhood Protection Act was amended from 24 to 22 completed weeks of gestation in 1991 based on the survival rate of extremely preterm infants. Survival rates of infants at 22 and 23 weeks' gestation born between 2002 and 2004 in Japan were 31% and 56%, respectively. Though medical data are the most important means to define viability, socio-economical and ethical factors should be also considered, especially when we discuss the group of marginally viable infants. We think there are two different categories of viability limits, one from biological survival limit and another from social agreement of providing active medical intervention. Currently in Japan, the former viability definition based on purely medical data is 22 completed weeks and the latter definition is the social consensus of about 24-28 weeks' gestation.

Entities:  

Mesh:

Year:  2009        PMID: 19673680     DOI: 10.1515/JPM.2009.112

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  2 in total

1.  Neonatal Outcomes of Very Low Birth Weight Infants in Korean Neonatal Network from 2013 to 2016.

Authors:  Jang Hoon Lee; O Kyu Noh; Yun Sil Chang
Journal:  J Korean Med Sci       Date:  2019-01-28       Impact factor: 2.153

2.  Comparison of mortality and survival without major morbidities of very preterm infants with very low birth weight from Japan and Brazil.

Authors:  Caroline Kaori Tomo; Olukunmi Omobolanle Balogun; Josy Davidson; Ruth Guinsburg; Maria Fernanda Branco de Almeida; José Maria de Andrade Lopes; Marina Carvalho de Moraes Barros; Kenji Takehara; Masashi Mikami; Tetsuya Isayama; Ai Hoshino; Rintaro Mori; Masashi Mizuguchi
Journal:  Rev Paul Pediatr       Date:  2022-09-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.